Cargando…
Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis
Patients with interstitial lung disease can develop a progressive fibrosing phenotype characterised by an irreversible, progressive decline in lung function despite treatment. Current therapies slow, but do not reverse or stop, disease progression and are associated with side-effects that can cause...
Autores principales: | Kolb, Martin, Crestani, Bruno, Maher, Toby M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9949383/ https://www.ncbi.nlm.nih.gov/pubmed/36813290 http://dx.doi.org/10.1183/16000617.0206-2022 |
Ejemplares similares
-
Targeting Human Herpesviruses: An Effective Strategy for Treating Idiopathic Pulmonary Fibrosis?
por: Maher, Toby M.
Publicado: (2021) -
Phase I studies of BI 1015550, a preferential phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis
por: Maher, Toby M., et al.
Publicado: (2022) -
Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice
por: Udalov, Sergey, et al.
Publicado: (2010) -
Correction to: Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice
por: Udalov, Sergey, et al.
Publicado: (2022) -
Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
por: Maher, Toby M., et al.
Publicado: (2019)